Can ZLAB sustain its EPS momentum in 2025?

**Zai Lab's (ZLAB) potential to sustain its EPS momentum in 2025 appears promising**, considering the following points: 1. **Consistent Growth Trajectory**: ZLAB has demonstrated significant growth, with a 53% surge over the past six months and a remarkable 1-year change of 144.51%. This consistent growth indicates a strong underlying performance that could support continued EPS momentum. 2. **Positive Analyst Ratings and Projections**: Analysts have highlighted ZLAB's growth potential, with Scotiabank projecting the company to become cash flow positive by the fourth quarter of 2025. This positive outlook, coupled with the potential impact of key drugs like Bemarituzumab and repotrectinib, suggests confidence in ZLAB's future earnings potential. 3. **Strong Pipeline and Strategic Focus**: ZLAB's focus on oncology and immunology, along with its robust pipeline, positions it well for sustained growth. The company's strategic initiatives and the anticipated contributions of key drugs to 2026 revenue indicate a forward-looking approach that could support continued EPS growth. 4. **Financial Health and Cash Position**: ZLAB's financial health, with a "Fair" overall score and a strong cash position of $730 million, provides a solid foundation for sustaining its EPS momentum. The company's ability to invest in patient acquisition and transition to maintenance treatment suggests a strategic approach to managing its financial resources effectively. In conclusion, while there are no available data on ZLAB's EPS in 2025, the company's strong growth trajectory, positive analyst ratings, strategic focus, and financial health suggest that it is well-positioned to sustain its EPS momentum.